Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Inhibition of Galectins with Small Molecules

In English

Författare

Summary, in English

Evidence that the galectin family of proteins plays crucial roles in cancer, inflammation, and immunity has accumulated over the last decade. The galectins have consequently emerged as interesting drug targets. A majority of galectin functions occurs by means of cross-linking glycoproteins and by doing so controlling gly-coproteirl cellular localization and residence times. The glycoprotein cross-linking occurs when galectin dimers or multimers, or galectins with two binding sites, bind galactose-containing glycans of the glycoproteins. Such galectin-glycan interactions have been successfully blocked with compounds having multivalent presentation of galactose, lactose, or N-acetyllactosamine, with peptides, and with small carbohydrate (galactose) derivatives. This review summarizes and analyzes attempts to develop efficient and selective small-molecule galectin inhibitors through derivatization of monosaccharides, mainly galactosides, with non-carbohydrate structures that protrude into subsites adjacent to the core-conserved galactose-recognizing site of the galectins.

Avdelning/ar

Publiceringsår

2011

Språk

Engelska

Sidor

18-23

Publikation/Tidskrift/Serie

Chimia

Volym

65

Issue

1-2

Dokumenttyp

Artikel i tidskrift

Förlag

Swiss Chemical Society

Ämne

  • Microbiology in the medical area
  • Immunology in the medical area

Nyckelord

  • Cancer
  • Galectin
  • Immunity
  • Inflammation
  • Inhibitor

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 0009-4293